1. Norway Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BerGenBio ASA

BerGenBio ASA

BRRGF
BerGenBio ASAUS flagOther OTC
97.09
USD
- -
- -
9.49BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.01
- -
- -
- -
238.44
848.59
44.38
48.69
28.13
0.02
10.92
- -
1.54
Basic EPS, GAAP
-1.16
-7,887.44
-14,198.1
-21,792.61
-19,580.01
-19,000.57
-18,981.54
-19,460.53
-21,843.83
-8.52
-561.04
- -
-253.33
Free Cash Flow per Basic Share
-1.08
-6,880.55
-13,626.01
-20,146.87
-19,088.53
-17,799.68
-17,307.22
-19,081.59
-20,839.49
-10.08
-359.13
- -
-278.72
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.05
271.17
368.52
597.06
558.66
582.38
644.41
556.46
641.02
3.57
-2,511.22
- -
-1,141.41
Tangible Book Value per Share
2.44
7,082.37
16,765.48
41,902.88
34,440.93
20,952.9
49,496.27
24,182.36
6,398.53
5.71
433.52
- -
197.04
Basic Weighted Avg Shares
50
- -
- -
- -
- -
- -
- -
- -
- -
22
- -
- -
1
Sales/Revenue/Turnover
1
- -
- -
- -
2
9
1
1
- -
- -
3
23
1
Operating Margin (%)
-9,836.79
- -
- -
- -
-8,331.43
-2,296.34
-43,442.93
-40,628.17
-78,569.41
-54,186.16
-5,211.07
-593.35
-17,833.73
Depreciation Expense
- -
- -
- -
- -
- -
1
1
1
1
- -
15
11
- -
Net Income, GAAP
-58
-72
-130
-182
-192
-199
-257
-309
-302
-190
-140
-155
-139
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-9,662.21
- -
- -
- -
-8,211.86
-2,239.08
-42,766.89
-39,969.51
-77,666.32
-53,785.59
-5,137.45
-673.13
-16,424.65
Working Capital
126
70
153
350
337
219
669
384
89
127
84
129
84
LT Debt
- -
1
- -
- -
- -
- -
1
1
- -
- -
5
1
5
Total Equity
122
65
153
350
337
220
670
384
88
127
108
146
108
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-2,946.75
-4,439.09
-4,358.52
-3,665.24
-3,442.06
-3,465.4
-3,521.1
-3,411.5
-430.28
-199.23
-159.9
-465.89

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
- -
- -
3
LT Borrowings
- -
- -
1
LT Finance Leases
- -
- -
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
28,424
28,272
1,565

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
218
195
142
Cash, Cash Equivalents & STI
200
175
131
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
43
41
58
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
37.62%
-11.11%
35.07%
Free Cash Flow
15.69%
-2.55%
44.84%
Net Income, GAAP
12.38%
-6.94%
10.61%
Sales/Revenue/Turnover
- -
277.02%
744.16%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
1
3
2025
- -
- -
- -
- -
23

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-5,204.05
-929.73
-68.31
-1.01
-8.52
2024
-86.08
-88.83
-40.68
-46.94
-561.04
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Oystein Soug
Full Time Employees
13
Sector
Healthcare
Industry
Biotechnology
Address
Jonas Lies vei 91 Bergen Norway 5009
IPO Date
Jul 23, 2018
Website
bergenbio.com
Similar Companies
Savara Inc. (SVRA)
SinoMab BioScience Limited (3681.HK)
Veru Inc. (VERU)
bluebird bio, Inc. (BLUE)
Cybin Inc. Common Stock (HELP)
Immunotech Laboratories, Inc. (IMMB)
Business
BerGenBio ASA, a clinical-stage biopharmaceutical company focused on developing selective AXL inhibitors for aggressive diseases including advanced treatment-resistant cancers and severe respiratory infections, completed a statutory merger with Oncoinvent ASA on October 29, 2025, under which BerGenBio serves as the acquiring entity; the combined company was renamed Oncoinvent ASA and now advances Oncoinvent's late-stage oncology pipeline featuring radiopharmaceutical therapies alongside BerGenBio's prior assets. Prior to the merger, BerGenBio's core products encompassed bemcentinib (formerly BGB324), a first-in-class highly selective oral small molecule AXL kinase inhibitor in Phase II trials for non-small cell lung cancer, acute myeloid leukemia, and other solid tumors; BGB149, a wholly owned humanized anti-AXL monoclonal antibody in Phase I testing; and preclinical assets including an outlicensed AXL antibody for antibody-drug conjugate development with ADC Therapeutics SA; the company halted all bemcentinib development activities in early 2025 following closure of its lead BGBC016 trial in STK11-mutated NSCLC. The merger, approved by BerGenBio's Extraordinary General Meeting on August 4, 2025, integrates BerGenBio's capital resources and Oslo Stock Exchange listing (ticker shifted to ONCIN) with Oncoinvent's Radspherin, an alpha-emitting radiopharmaceutical microparticle therapy targeting peritoneal carcinomatosis in ovarian cancer and other abdominal malignancies via intraperitoneal administration; post-merger, a fully underwritten NOK 130 million rights issue commenced in November 2025 to fund clinical advancement, including Oncoinvent's ongoing randomized Phase 2 trial of Radspherin, with board and management transitioning to Oncoinvent's leadership plus BerGenBio's former CEO Olav Hellebø. Founded in 2007 and headquartered at Nygårdsgaten 114 in Bergen, Norway, BerGenBio (now Oncoinvent ASA) operates in the biotechnology sector serving global oncology and infectious disease markets through strategic partnerships, investigator-sponsored trials, and companion diagnostics for AXL-positive patient selection; the entity employs approximately 13 staff and maintains a lean structure post cost-containment measures implemented in 2025.

Company News

APIChatGPT